Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s

Multiple myeloma (MM) is the second most prevalent hematologic malignancy. Although the use of bortezomib (BTZ) significantly improves MM therapy, intrinsic and acquired drug resistance to BTZ remains a major clinical problem. In this study, we find that Cdc37, a key co-chaperone of Hsp90, is downre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogenesis (New York, NY) NY), 2020-03, Vol.9 (3), p.31, Article 31
Hauptverfasser:	Zang, Meirong, Guo, Jiaojiao, Liu, Lanting, Jin, Fengyan, Feng, Xiangling, An, Gang, Qin, Xiaoqi, Wu, Yangbowen, Lei, Qian, Meng, Bin, Zhu, Yinghong, Guan, Yongjun, Deng, Shuhui, Hao, Mu, Xu, Yan, Zou, Dehui, Wu, Minghua, Qiu, Lugui, Zhou, Wen
Format:	Artikel
Sprache:	eng
Schlagworte:	13/109 13/2 13/31 14 14/35 631/67/1990 631/67/395 Apoptosis Bortezomib Cell Biology Cell differentiation Drug resistance Hsp90 protein Human Genetics Internal Medicine Malignancy Medicine Medicine & Public Health Multiple myeloma Oncology Plasma Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!